2021 AAPM Virtual 63rd Annual Meeting - Session: Outcome modeling and assessment
Tweet #linkwatch again, browse/search all videos, go back to the previous page, or watch another video in this session (see below). add this video to a playlist.
All videos in this session:
Compact Neural Network to Predict Radiation-Induced Lymphocyte Depletion - Yejin Kim KAIST | |
MRI-Based Multi-Region Delta-Radiomics for Prediction of Recurrence After Chemoradiotherapy in Locally Advanced Cervical Cancer - Masashi Kawamura | |
Predicting Osteoradionecrosis From Head and Neck Radiotherapy Using a Residual convolutional Neural Network - Brandon Reber University of Texas-MD Anderson Cancer Center | |
Relationship Between Coronary Artery Radiation Doses and Risk of Late Coronary Artery Disease: A Report From the Childhood Cancer Survivor Study (CCSS) - Suman Shrestha, MS University of Texas MD Anderson Cancer Center | |
Seed Spots Analysis to Characterize Linear-Energy-Transfer (LET) Effect in the Adverse Event Regions of Head and Neck Cancer Patients Treated by Intensity-Modulated Proton Therapy (IMPT) - Yunze Yang Mayo Clinic Arizona | |
Survival Prediction Models for Patients with Malignant Pleural Mesothelioma After Adjuvant Radiotherapy - Zitian Wang UCLA School of Medicine | |
Q & A - |





















Compact Neural Network to Predict Radiation-Induced Lymphocyte Depletion
MRI-Based Multi-Region Delta-Radiomics for Prediction of Recurrence After Chemoradiotherapy in Locally Advanced Cervical Cancer
Predicting Osteoradionecrosis From Head and Neck Radiotherapy Using a Residual convolutional Neural Network
Relationship Between Coronary Artery Radiation Doses and Risk of Late Coronary Artery Disease: A Report From the Childhood Cancer Survivor Study (CCSS)
Seed Spots Analysis to Characterize Linear-Energy-Transfer (LET) Effect in the Adverse Event Regions of Head and Neck Cancer Patients Treated by Intensity-Modulated Proton Therapy (IMPT)
Survival Prediction Models for Patients with Malignant Pleural Mesothelioma After Adjuvant Radiotherapy
Q & A